Healthcare
A revised Paxlovid supply agreement with the U.S. government has pushed Pfizer to launch a “cost realignment” program including layoffs, though it is still unclear how many employees will be affected.
Dialysis giant DaVita on Thursday raised concerns over Novo Nordisk’s interim analysis of a kidney outcomes study of semaglutide, pointing to the potentially limited applicability of the findings.
Maximizing the true potential of Ozempic—and similar drugs—requires a partnership between drug developers, healthcare providers and patients.
The call to develop therapeutics that interfere with aging, helping people live longer, healthier lives, is increasing—and experts say the market opportunity is high.
As MSLs take on greater roles in healthcare, standardization is crucial to fostering trust.
Despite filing respective lawsuits challenging the program, AstraZeneca and Bristol Myers Squibb have decided to participate in the first round of price negotiations under the Inflation Reduction Act.
The COVID-19 pandemic highlighted a need for local production of vaccines. Now, German pharma company BioNTech has said it will start manufacturing vaccines in Africa.
A new study provides the first empirical evidence that the not-for-profit manufacturer’s business model can lead to robust drug supplies and lower medicine costs.
As the CEO of WCG, Srivastava has his sights set on changing the current makeup of clinical health trials to do good globally.
In addition to massive revenues predicted for their developers, Leqembi—and possibly donanemab, if approved—should bring in substantial dollars to the healthcare industry.
PRESS RELEASES